Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

AG Mortgage Investment Trust Inc MITT.PR.B


Primary Symbol: MITT Alternate Symbol(s):  MITT.PR.A

AG Mortgage Investment Trust, Inc. is a residential mortgage real estate investment trust (REIT) with a focus on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the United States mortgage market. The Company focuses its investment activities primarily on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market. The Company obtains its assets through Arc Home, LLC, its residential mortgage loan originator, and through other third-party origination partners. Its investment portfolio (which excludes its ownership in Arc Home) includes residential investments and agency residential mortgage-backed securities (RMBS). Its residential investments consist of newly originated non-agency loans and agency-eligible loans. Its agency RMBS represent interests in pools of residential mortgage loans guaranteed by a government-sponsored enterprise (GSE). Its manager is AG REIT Management, LLC.


NYSE:MITT - Post by User

Post by LeaMileson Jun 03, 2022 5:35am
180 Views
Post# 34728791

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance



FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.



<< Previous
Bullboard Posts
Next >>